As ICER’s draft report acknowledges, plaque psoriasis is a common disease that can impact patients’ quality of life and daily functioning. With no cure available, patients have historically managed the condition with therapies such as methotrexate. Newer targeted and biologic therapies, however, can improve the duration and level of symptom relief that patients can achieve. 2
In the interest of patients’ ability to access these treatments, IfPA is pleased that ICER’s analyses show all targeted agents to be cost-effective and to carry a budget impact below ICER’s limit.
IfPA does have concerns, however, that ICER’s conclusions diverge from the results of its analyses.